-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to statistics, more than 500,000 women worldwide die of breast cancer every yea.
Research has shown that artificial intelligence (AI) has shown valuable results in detecting breast cancer during mammograph.
Recently, a study published in the journal Radiology compared the diagnostic performance of commercially available artificial intelligence systems with independent double-reading performed by radiologists at BreastScreen in Norway, while also exploring the histopathological features of breast cancer with different AI score.
This retrospective study included 122,969 screening exams from 47,877 women performed at four screening units at BreastScreen in Norway between October 2009 and December 2018. The dataset included 752 screen-detected breast cancers (1 per 1000 examinations) and 205 interval breast cancers (7 per 1000 examinations.
A total of 653 (88%) of 752 screened cancers and 92 (49%) of 205 interval cancers were scored 10 points (threshold 1) by the AI syste.
The present study shows that the proportion of screened breast cancers not selected by artificial intelligence (AI) systems is less than 20% at three assessed thresholds, some of which may be detected at an early stage in the next round of screenin.
Original source:
Marthe Larsen, Camilla F Aglen, Christoph I Lee, et a.